KIM AUSTIN D.
Known title: EVP & General CounselCIK: 0001746240
Associated companies
Transaction History
| ACAD | ▼ Sell | Open Market | 590 | $18K | 1/8/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,634 | — | 1/6/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 16,369 | $359K | 10/6/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 36,174 | — | 10/5/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 917 | $19K | 5/1/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,005 | — | 4/29/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,456 | $26K | 4/6/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 4,773 | — | 4/5/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 803 | $15K | 2/24/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,214 | — | 2/23/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 589 | $10K | 1/9/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,633 | — | 1/6/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 894 | $16K | 5/2/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,005 | — | 4/29/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,213 | $0 | 2/23/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 782 | $19K | 2/23/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,633 | — | 1/6/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 574 | $13K | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.